2017 U.S. Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Supplier Shares by Country and Segment Forecasts, Emerging Technologies, Competitive Strategies [Report Updated: 23082017] Prices from USD $2750
Complete report $2,750. nbsp;DataPack test volumes, sales forecasts, supplier shares $1,750.
The report is available by section, market segment, and can be customtailored to your specific information needs and budget.
This new study from VPGMarketResearchnbsp;contains 430 pages, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years.
Report Highlights
Market shares of leading suppliers
Business and technological trends in major markets
Fiveyear test volume and sales forecasts
Market shares of leading competitors
Feature comparison of major analyzers
Strategic profiles of leading market players and startup firms developing innovative products
Specific product and business opportunities for instrument and consumable suppliers.
Rationale
Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of costeffective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.
U.S. Market Overview
Laboratories performing DNA sequencing and molecular diagnostic testingnbsp;by country and market segment.
Fiveyear test volume and sales projections.
Market Segmentation Analysis
Fiveyear test volume and sales projections:
Infectious Diseasesnbsp;nbsp;nbsp;nbsp;nbsp; nbsp;nbsp; Forensic Testing
Cancernbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp; Paternity Testing/HLA Typing
Genetic Diseasesnbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp; nbsp;nbsp;nbsp;nbsp; Others
A comprehensive analysis of the sequencing market by laboratory segment.
Detailed market segmentation analysis, including review of the market dynamics, trends,
nbsp; structure, size, growth and major suppliers.Product/Technology Review
Comparison of the major molecular diagnosticnbsp;analyzers.
Extensive review of molecular diagnostic technologies, test formats, detection methodologies,
nbsp; trends in testing automation and over target/signal amplification methods.Worldwide listings of companies, universities and research centers developing new molecular
nbsp;nbsp; diagnosticnbsp;technologies and products.Competitive Assessments
Extensive strategic assessments of major suppliers and emerging market entrants,
nbsp;nbsp;including their sales, product portfolios, marketing tactics, collaborative arrangements and
nbsp;nbsp;new technologies/products in Ramp;D.nbsp;nbsp; Abbott
nbsp;nbsp; Affymetrix
nbsp;nbsp; Agilent Technologies
nbsp;nbsp; Applied Gene Technologies
nbsp;nbsp; Arca Biopharma
nbsp;nbsp; Beckman Coulter/Danaher
nbsp;nbsp; Becton Dickinson
nbsp;nbsp; Biokit
nbsp;nbsp; BioMerieux
nbsp;nbsp; BioRad
nbsp;nbsp; Biotest
nbsp;nbsp; CellMark Forensics/LabCorp
nbsp;nbsp; Cepheid
nbsp;nbsp; Decode Genetics
nbsp;nbsp; Diadexus
nbsp;nbsp; Eiken
nbsp;nbsp; Elitech Group
nbsp;nbsp; Enzo
nbsp;nbsp; Exact Sciences
nbsp;nbsp; Fujirebio
nbsp;nbsp; Grifols
nbsp;nbsp; Hologic/GenProbe
nbsp;nbsp; Illumina
nbsp;nbsp; Kreatech/Leica
nbsp;nbsp; LiCor Biosciences
nbsp;nbsp; Monogram Biosciences
nbsp;nbsp; Myriad Genetics
nbsp;nbsp; OrthoClinical Diagnostics
nbsp;nbsp; Perkin Elmer/Caliper
nbsp;nbsp; Proteome Sciences
nbsp;nbsp; Qiagen
nbsp;nbsp; Roche
nbsp;nbsp; Scienion
nbsp; nbsp; Sequenom
nbsp; nbsp; Shimadzu
nbsp; nbsp; Siemens
nbsp; nbsp; Sierra Molecular
nbsp; nbsp; Takara Bio
nbsp; nbsp; Tecan Group
nbsp;nbsp; Thermo FisherComprehensive listings of companies developing and marketing molecular
nbsp; diagnostic products, by test and application.Opportunities and Strategic Recommendations
Specific new product development opportunities with potentially significant market appeal
nbsp;nbsp;during the next five years.Design criteria for new products.
Alternative market penetration strategies.
Potential market entry barriers and risks.
Business planning issues and concerns.
Contains 430 pages
NEXT ARTICLE
More From BioPortfolio on "2017 U.S. Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Supplier Shares by Country and Segment Forecasts, Emerging Technologies, Competitive Strategies [Report Updated: 23082017] Prices from USD $2750"
